Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
James R. Porter, President and CEO and a director of Nuvalent, Inc. (NUVL), reported multiple transactions on 08/15/2025 under a pre-existing Rule 10b5-1 trading plan adopted April 2, 2024. He acquired 27,000 shares by exercising stock options at an $18.93 exercise price and simultaneously sold 27,000 shares across three blocks (20,035; 6,865; 100) at weighted average prices of approximately $75.22, $75.98, and $76.90, respectively.
Following these transactions his beneficial ownership of Class A common stock decreased from 276,062 to 249,062 shares. The option underlying the 27,000 shares vests per the grant schedule with an expiration date of 01/04/2032. The filing was signed by an attorney-in-fact on 08/19/2025.
Nuvalent insider activity: option exercises and a planned sale under a 10b5-1 plan. Henry E. Pelish, Nuvalent's Chief Scientific Officer, acquired shares through option exercises and sold shares pursuant to a pre-established trading plan. On 08/07/2025 Pelish exercised options to acquire 731 shares at $18.93, 877 shares at $27.85 and 3,892 shares at $29.33, and sold 5,500 shares at $74.85. After these transactions his reported direct beneficial ownership is 60,956 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted November 1, 2024, and includes vesting schedules for the options.
Nuvalent, Inc. (NUVL) – Form 144 filing discloses a planned resale of 4,253 Class A common shares, valued at roughly $349,086, through Goldman Sachs & Co. LLC on or after 24 Jul 2025.
The shares were originally acquired in two public offerings (3,535 on 02 Aug 2021 and 718 on 03 Nov 2022) and equal just ~0.006% of the 66.4 million shares outstanding, implying negligible impact on float or dilution because Rule 144 covers already-issued stock. No sales have occurred in the past three months, and the seller certifies possession of no material non-public information.
The notice contains no operational or earnings data and does not involve new capital for the company; however, investors may view insider disposition—albeit small—as a sentiment indicator to be weighed against broader fundamentals.
Nuvalent, Inc. (NUVL) Form 144 reports a planned insider sale of 156,670 Class A common shares, equal to roughly 0.24 % of the 66.37 million shares outstanding. The proposed transaction, to be executed through Goldman Sachs & Co. LLC, carries an aggregate market value of $12.86 million, implying a reference price near $82 per share. The approximate sale date listed is 24 July 2025 on Nasdaq.
The shares were originally acquired on 30 April 2021 via a purchase of preferred stock that automatically converted to common immediately prior to Nuvalent’s IPO. The filer reports no other share sales in the past three months and certifies that no undisclosed material adverse information is known.
While the notice signals insider intent to monetize a portion of holdings, the size is modest versus float and does not by itself alter Nuvalent’s operating outlook. Investors may monitor subsequent Form 4 filings for execution details and gauge any short-term supply effects.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
